Piperacillin/Tazobactam Fresenius 2 g/0,25 g/4 g/0,5 g Solution

PIPERACILLIN/TAZOBACTAM FRESENIUS is indicated for the treatment of the following systemic and/or local bacterial infections in which susceptible organisms have been detected or are suspected:

Adults:

• Community acquired pneumonia due to Haemophilus influenzae.
• Intra-abdominal infections caused by piperacillin resistant beta-Iactamase producing strains of Escherichia coli and Bacteroides fragilis.
• Skin and skin structure infections caused by piperacillin resistant beta-Iactamase producing strains of methicillin-sensitive Staphylococcus aureus.
• Gynaecologic infections including endometritis caused by piperacillin resistant beta-Iactamase producing strains of E coli.
• PIPERACILLIN/TAZOBACTAM FRESENIUS plus an aminoglycoside is indicated for bacterial infections in neutropenic patients.

Children:

Children under the age of 12 years: PIPERACILLIN/TAZOBACTAM FRESENIUS plus an aminoglycoside is indicated for bacterial infections in neutropenic patients.

Children 2-12 years: In hospitalised children aged 2 to 12 years, PIPERACILLIN/TAZOBACTAM FRESENIUS is indicated for the treatment of serious intra-abdominal infections, caused by E. coli or Bacteroides species. PIPERACILLIN/TAZOBACTAM FRESENIUS has not been evaluated in this indication for paediatric patients below the age of 2 years. While PIPERACILLIN/TAZOBACTAM FRESENIUS is indicated only for the conditions listed above, infections caused by piperacillin susceptible organisms are also amenable to PIPERACILLIN/TAZOBACTAM FRESENIUS treatment due to its piperacillin content. Therefore, the treatment of mixed infections caused by piperacillin susceptible organisms and beta-Iactamase producing organisms susceptible to PIPERACILLIN/TAZOBACTAM FRESENIUS should not require the addition of another antibiotic. PIPERACILLIN/TAZOBACTAM FRESENIUS is useful in the treatment of mixed infections and in presumptive therapy prior to the availability of the results of sensitivity tests.

Posology

Adults and juveniles 12 years and older: The usual dosage for adults and juveniles with normal renal function is 4 g/0,5 g PIPERACILLIN/TAZOBACTAM FRESENIUS given every eight hours. The dosage in immunocompromised and neutropenic patients with infection is 4 g/0,5 g PIPERACILLIN/TAZOBACTAM FRESENIUS every 6 hours in combination with an aminoglycoside.

Children under the age of 12 years: PIPERACILLIN/TAZOBACTAM FRESENIUS is only recommended for the treatment of children with neutropenia. For children weighing over 50 kg, follow the adult dosing guidance, including the aminoglycoside. For children with normal renal function and weighing less than 50 kg the dose should be adjusted to 90 mg/kg (80 mg piperacillin/10 mg tazobactam) administered every 6 hours, in combination with an aminoglycoside.

Elderly: PIPERACILLIN/TAZOBACTAM FRESENIUS may be used at the same dose levels as adults except in cases of renal impairment (see below).

Renal insufficiency: In patients with renal insufficiency, the intravenous dose should be adjusted to the degree of actual renal function impairment. The suggested daily doses are as follows:

Intravenous dosage schedule for adults with impaired renal function:

For patients on haemodialysis, the maximum daily dose is 2 g/0,25 g every 8 hours of PIPERACILLIN/TAZOBACTAM FRESENIUS. In addition, because haemodialysis removes 30 % u2013 40 % of piperacillin in 4 hours, one additional dose of 6 g/0,75 g should be administered following each dialysis period. For patients with renal failure and hepatic insufficiency, measurement of serum levels of PIPERACILLIN/TAZOBACTAM FRESENIUS will provide additional guidance for adjusting dosage.

Neutropenic patients: In treating neutropenic patients, full therapeutic doses of PIPERACILLIN/TAZOBACTAM FRESENIUS and an aminoglycoside should be used. The possibility of hypokalaemia should be kept in mind in patients who have low potassium reserves, and periodic electrolyte determinations should be made in these patients.

Duration of therapy: In acute infections, treatment with PIPERACILLIN/TAZOBACTAM FRESENIUS should be for a minimum of five days and continued for forty-eight hours beyond resolution of clinical symptoms or the fever. The usual duration of treatment is 7 u2013 10 days.

Hospitalised children with intra-abdominal infection: For children aged 2 to 12 years, weighing up to 40 kg, and with normal renal function, the recommended dosage is 112,5 mg/kg (100 mg piperacillin/12,5 mg tazobactam) every 8 hours. For children aged 2 to 12 years, weighing over 40 kg, and with normal renal function, follow the adult dose guidance, i.e. 4,5 g (4 g piperacillin/0,5 g tazobactam) every 8 hours. The duration of therapy should be guided by the severity of the infection and the patient's clinical and bacteriological progress. Therapy is recommended to be a minimum of 5 days and a maximum of 14 days, considering the dose administration should continue at least 48 hours after the resolution of clinical signs and symptoms.

Children aged 2 u2013 12 years with renal insufficiency: The pharmacokinetics of PIPERACILLIN/TAZOBACTAM FRESENIUS have not been studied in paediatric patients with renal impairment. The following dosage adjustment for paediatric patients aged 2 to 12 years with renal impairment is recommended.

Intravenous dosage schedule for children aged 2 u2013 12 years with impaired renal function:

The dosage modification is only an approximation. Each patient must be monitored closely for signs of medicine toxicity. PIPERACILLIN/TAZOBACTAM FRESENIUS dose and interval should be adjusted accordingly.

Method of administration: PIPERACILLIN/TAZOBACTAM FRESENIUS must be given by slow intravenous infusion (30 minutes). Prior to administration, each vial of PIPERACILLIN/TAZOBACTAM FRESENIUS must be reconstituted and may be further diluted to the desired volume. For information on instructions for reconstitution and dilution, see section 6.6.

The use of PIPERACILLIN/TAZOBACTAM FRESENIUS is contraindicated in patients with a history of allergic reactions to piperacillin, tazobactam or any of the penicillins and/or cephalosporins or beta-lactamase inhibitors, or any of the other ingredients of PIPERACILLIN/TAZOBACTAM FRESENIUS (listed in section 6.1).

Hypersensitivity reactions: Serious and occasionally fatal hypersensitivity (anaphylactic/anaphylactoid, including shock) reactions have been reported in patients receiving therapy with penicillins, including PIPERACILLIN/TAZOBACTAM FRESENIUS. These reactions are more likely to occur in persons with a history of penicillin hypersensitivity or sensitivity to multiple allergens. There have been reports of patients with a history of penicillin hypersensitivity that have experienced severe hypersensitivity reactions when treated with a cephalosporin. Before initiating therapy with PIPERACILLIN/TAZOBACTAM FRESENIUS, careful inquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins, and other allergens. If an allergic reaction occurs during therapy with PIPERACILLIN/TAZOBACTAM FRESENIUS, the antibiotic should be discontinued. Serious hypersensitivity reactions require immediate emergency measures, with epinephrine (adrenaline), corticosteroids and antihistamines. An open airway must be maintained.

Serious skin reactions: Serious skin reactions, such as erythema multiforme, bullous dermatitis, exanthema, toxic epidermal necrolysis, Stevens-Johnson syndrome have been reported (see section 4.8). Patients should be monitored closely if they develop a skin rash and PIPERACILLIN/TAZOBACTAM FRESENIUS should be discontinued if lesions progress.

Clostridium difficile associated diarrhoea, including colitis: Pseudomembranous colitis has been reported with nearly all antibacterial medicines, including piperacillin. Antibiotic-induced pseudomembranous colitis may be manifested by severe, persistent diarrhoea which may be life-threatening. The onset of pseudomembranous colitis may occur during or after antibacterial treatment. Therefore, it is important to consider this diagnosis in patients who present with diarrhoea subsequent to the administration of PIPERACILLIN/TAZOBACTAM FRESENIUS. After the diagnosis of pseudomembranous colitis has been established, therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond to medicine discontinuation alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation and treatment with an oral antibacterial medicine effective against C. difficile. In case of severe, persistent diarrhoea, the possibility of antibiotic-induced life-threatening pseudomembranous colitis must be taken into consideration. Therefore, PIPERACILLIN/TAZOBACTAM FRESENIUS must be discontinued immediately in such cases and suitable therapy be initiated (e.g. oral teicoplanin or oral vancomycin). Preparations which inhibit peristalsis, are contraindicated.

Haematology: Leucopenia and neutropenia may occur, especially during prolonged therapy. Therefore, periodic assessment of haematopoietic function should be performed. Bleeding manifestations have occurred in some patients receiving beta-Iactam antibiotics. These reactions have sometimes been associated with abnormalities of coagulation tests such as clotting time, platelet aggregation and prothrombin time and are more likely to occur in patients with renal failure. If bleeding manifestations occur, the antibiotic should be discontinued and appropriate therapy instituted.

Haemophagocytic lymphohistiocytosis (HLH): Cases of HLH have been reported in patients treated with PIPERACILLIN/TAZOBACTAM FRESENIUS, often following treatment longer than 10 days. HLH is a life-threatening syndrome of pathologic immune activation characterised by clinical signs and symptoms of an excessive systemic inflammation (e.g. fever, hepatosplenomegaly, hypertriglyceridaemia, hypofibrinogenaemia, high serum ferritin, cytopenias and haemophagocytosis). Patients who develop early manifestations of pathologic immune activation should be evaluated immediately. If diagnosis of HLH is established, PIPERACILLIN/TAZOBACTAM FRESENIUS treatment should be discontinued.

Resistance: The use of PIPERACILLIN/TAZOBACTAM FRESENIUS may result in overgrowth of non-susceptible organisms, including fungi. The possibility of the emergence of resistant organisms, which might cause superinfections, should be kept in mind, particularly during prolonged treatment. If this occurs, appropriate measures should be taken.

Neurological effects: Patients may experience neuromuscular excitability or convulsions if higher than recommended doses are given intravenously, especially in patients with impaired renal function.

Hypokalaemia: Periodic electrolyte determinations should be made in patients with low potassium reserves, and the possibility of hypokalaemia should be kept in mind with patients who have potentially low potassium reserves and who are receiving cytotoxic therapy or diuretics.

Liver function: Modest elevation of indices of liver function may be observed.

Renal impairment: In patients with renal insufficiency or haemodialysis patients, the intravenous dose should be adjusted to the degree of renal function impairment. Periodic assessment of renal and hepatic systems during prolonged therapy is advisable.

Age: In patients over 65 years dosage should be adjusted in the presence of renal insufficiency.

Sodium content: This product contains 2,4 mmol (56 mg) of sodium per gram of piperacillin which may increase a patient's overall sodium levels.

Probenecid: Concurrent administration of probenecid and PIPERACILLIN/TAZOBACTAM FRESENIUS produced a longer half-life and lower renal clearance for both piperacillin and tazobactam; however, peak plasma concentrations of either medicine are unaffected.

Oral anticoagulants: During simultaneous administration of high doses of heparin, warfarin, oral anticoagulants, NSAIDs and other medicines that may affect the blood coagulation system and/or the thrombocyte function, the coagulation parameters should be tested more frequently and monitored regularly.

Non-depolarising muscle relaxants: Piperacillin, when given concomitantly with vecuronium has been implicated in the prolongation of the neuromuscular blockage of vecuronium. Due to their similar mechanism of action, it is expected that the neuromuscular blockade produced by any of the non-depolarising muscle relaxants could be prolonged in the presence of piperacillin.

Methotrexate: Piperacillin may reduce the excretion of methotrexate; therefore, serum levels of methotrexate should be monitored in patients to avoid medicine toxicity.

Other antibiotics: PIPERACILLIN/TAZOBACTAM FRESENIUS may also interact with bacteriostatic antibacterial medicines such as chloramphenicol and tetracyclines. No interaction is found between PIPERACILLIN/TAZOBACTAM FRESENIUS and vancomycin. Piperacillin either alone or with tazobactam did not significantly alter the pharmacokinetics of tobramycin in patients with normal renal function and with mild or moderate renal impairment. The pharmacokinetics of piperacillin, tazobactam and the M1 metabolite were also not significantly altered by tobramycin administration. Whenever PIPERACILLIN/TAZOBACTAM FRESENIUS is used concurrently with another antibiotic, especially an aminoglycoside such as tobramycin, the medicines must not be mixed in intravenous solutions or administered concurrently due to physical incompatibility (see sections 6.2 and 6.6).

Oral contraceptives: Effectiveness of oral contraceptives may be decreased by piperacillin/tazobactam, including PIPERACILLIN/TAZOBACTAM FRESENIUS.

Laboratory tests: The administration of PIPERACILLIN/TAZOBACTAM FRESENIUS may result in a false-positive reaction for glucose in the urine using a copper-reduction method. It is recommended that glucose tests based on enzymatic glucose oxidase reactions be used. The direct antiglobulin (Coombs) test may be positive. There have been reports of positive test results using the Bio-Rad laboratories Platelia Aspergillus EIA test in patients receiving PIPERACILLIN/TAZOBACTAM FRESENIUS injection who were subsequently found to be free of Aspergillus infection. Cross-reactions with non-Aspergillus polysaccharides and polyfuranoses with Bio-Rad laboratories Platelia Aspergillus EIA test have been reported. Therefore, positive test results in patients receiving PIPERACILLIN/TAZOBACTAM FRESENIUS should be interpreted cautiously and confirmed by other diagnostic methods.

Safety in pregnancy and lactation has not been established. Adequate studies on the use of PIPERACILLIN/TAZOBACTAM FRESENIUS during pregnancy and the period of breastfeeding are not yet available.

Pregnancy: Piperacillin and tazobactam cross the placenta. Studies in animals have shown developmental toxicity, but no evidence of teratogenicity, at doses that are maternally toxic.

Fertility: PIPERACILLIN/TAZOBACTAM FRESENIUS did not affect fertility in rats.

Breastfeeding: Safety has not been established. Piperacillin is excreted in low concentrations in human milk; tazobactam concentrations in human milk have not been studied. Woman receiving PIPERACILLIN/TAZOBACTAM FRESENIUS should not breastfeed their infants.

No studies on the effect of ability to drive or use machines have been performed.

Infections and infestations

Less frequent: Candidal superinfections, Clostridium difficile associated diarrhoea

Blood and the lymphatic system disorders

Frequent: Thrombocytopenia, prolonged activated partial thromboplastin time

Less frequent: Leucopenia, anaemia, epistaxis, eosinophilia, haemolytic anaemia, agranulocytosis, pancytopenia, prolonged prothrombin time/INR, thrombocytosis

Frequency unknown: Neutropenia, purpura, prolonged bleeding time

Immune system disorders

Less frequent: Hypersensitivity reaction, anaphylactic reaction (including shock)

Frequency unknown: Anaphylactoid reaction, anaphylactoid shock

Metabolism and nutrition disorders

Frequent: Decreased blood albumin, hypoalbuminaemia, decreased blood total protein

Less frequent: Hypokalaemia, decreased blood glucose, hypoglycaemia

Nervous system disorders

Frequent: Headache, insomnia

Cardiac disorders

Less frequent: Chest pain

Vascular disorders

Less frequent: Hypotension, phlebitis, thrombophlebitis, flushing

Gastrointestinal disorders

Frequent: Diarrhoea, abdominal pain, nausea, vomiting, constipation, dyspepsia

Less frequent: Stomatitis, pseudomembranous colitis

Hepato-biliary disorders

Frequent: Increased aspartate aminotransferase, increased alanine aminotransferase, increased blood alkaline phosphatase

Less frequent: Increased bilirubin, hyperbilirubinaemia, jaundice, hepatitis

Frequency unknown: Increased gamma-glutamyl transferase

Skin and subcutaneous tissue disorders

Frequent: Rash, pruritis

Less frequent: Urticaria, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis

Frequency unknown: Bullous dermatitis, maculopapular rash

Musculoskeletal, connective tissue and bone disorders

Less frequent: Arthralgia, myalgia

Renal and urinary disorders

Frequent: Increased blood creatinine, increased blood urea

Less frequent: Interstitial nephritis, renal failure

Frequency unknown: Tubulointerstitial nephritis

General disorders and administrative site conditions

Frequent: Fever, injection site reaction

Less frequent: Rigors, chills, fever and rash in cystic fibrosis patients

Investigations

Frequent: Positive direct Coombs (positive antiglobulin) test

Unknown frequencies cannot be established from the available data.

Reporting of suspected adverse reactions: Healthcare providers are asked to report any suspected adverse drug reactions to the Holder of the Certificate of Registration at the following email address: [email protected] and to the relevant medicineu2019s regulatory authority in the country where the product is marketed. Reporting suspected adverse reactions after authorisation of PIPERACILLIN/TAZOBACTAM FRESENIUS is important. It allows continued monitoring of the benefit/risk balance of PIPERACILLIN/TAZOBACTAM FRESENIUS. Healthcare providers are asked to report any suspected adverse reactions via the Adverse Drug Reaction Reporting Form, found online under SAHPRAu2019s publications: https://www.sahpra.org.za/Publications/Index/8.

Symptoms of overdose: See sections 4.4 and 4.8. The majority of events experienced during overdosage including nausea, vomiting and diarrhoea. Patients may experience neuromuscular excitability or convulsions if higher than recommended doses are given intravenously (particularly in the presence of renal failure).

Treatment of overdose: Treatment should be supportive and symptomatic according to the patient's clinical presentation. No specific antidote is known. Excessive serum concentrations of either piperacillin or tazobactam may be reduced by haemodialysis. In the event of an emergency, all required intensive medical measures are indicated as in the case of piperacillin. In case of motor excitability or convulsions, anticonvulsive medicines (e.g. diazepam or barbiturates) may be indicated. In case of severe, hypersensitivity (anaphylactic) reactions, the usual countermeasures are to be initiated (antihistamines, corticosteroids, sympathomimetic medicines and, if required, oxygen and airway management).